Abstract
Expanded access is a regulatory mechanism by which an investigational drug can be made available outside of a clinical trial to treat patients with serious or life-threatening conditions for which there are no satisfactory treatment options. An expanded access program (EAP) is the formal plan under which preapproval access to an investigational drug can be provided to a group of patients. Although an EAP is a regulated program, the decision to authorize an EAP is the responsibility of the biopharmaceutical sponsor. Because of the significant impact an EAP can have on current patients, drug development, and future patients, we propose that a sponsor’s decision must be based not only on regulatory criteria but also on ethical and practical considerations regarding implementation of an EAP. Such an approach will help ensure that decisions and plans uphold ethical precepts such as fairness, promoting good, and minimizing risk of harm.
Article PDF
Avoid common mistakes on your manuscript.
References
Rules and regulations (§312.305). Fed Regist. 2009;74(155). http://www.gpo.gov/fdsys/pkg/FR-2009-08-13/pdf/E9-19005.pdf. Accessed September 10, 2014.
Whitefield K, Huemer KH, Winter D, et al. Compassionate use of interventions: results of a European clinical research infrastructures network survey of ten European countries. Trials. 2010;11:104.
DiMasi JA, Feldman L, Seckler A, Wilson A. Trends in risks associated with new drug development: success rates for investigational drugs. Clin Pharmacol Ther. 2010;87(3):272–277.
Caplan A. Is it sound public policy to let the terminally ill access experimental medical innovations? Am J Bioeth. 2007;7(6):1–3.
Annas G. Cancer and the constitution: choice at life’s end. N Engl J Med. 2007;357(4):408–413.
Jacobson PD, Parmet WE. A new era of unapproved drugs: the case of Abagail Alliance v Von Eschenbach. JAMA. 2007;97(2):205–208.
Menikoff J. Beyond Abigail Alliance: the reality behind the right to get experimental drugs. Kansas Law Review. 2008;56:1045–1074.
Leonard EW. Right to experimental treatment: FDA new drug approval, constitutional rights, and the public’s health. J Law Med Ethics. 2009;37(2):269–279.
Shah S, Zettler P. From a constitutional right to a policy of exceptions: Abigail Alliance and the future of access to experimental therapy. Yale J Health Policy Law Ethics. 2013;10(1):137–196.
Bener S, Flicker L, Rhodes R. Access for the terminally ill to experimental medical innovations: a three-pronged threat. Am J Bioeth. 2007;7(10):3–6.
London AJ, Kimmelman J, Emborg ME. Beyond access vs. protection in trials of innovative therapies. Science. 2010; 328:829–830.
Schulenk U, Lowry C. Terminal illness and access to phase I experimental agents, surgeries and devices: reviewing the ethical arguments. Br Med Bull. 2009;89:7–22.
Chahal M. Off-trial access to experimental cancer agents for the terminally ill: balancing the needs of individuals and society. J Med Ethics. 2010;36:367–370.
Tuma RS. Expanded-access programs: little heard views from industry. Oncology Times. 2008;30(15):19, 22–23.
Childress J, Beauchamp T. Principles of Biomedical Ethics. New York, NY: Oxford University Press; 2009.
Persad G, Wertheimer A, Emanuel EJ. Principles for allocation of scarce medical interventions. Lancet. 2009;473:423–431.
Scheunemann LP, White DB. The ethics and reality of rationing in medicine. Chest. 2011;140(6):1625–1632.
Edwards SJL. Restricted treatments, inducements, and research participation. Bioethics. 2006;20:77–91.
National Breast Cancer Coalition. Access to investigational interventions outside of clinical trials: policy statement. http://www.breastcancerdeadline2020.org/breast-cancer-information/breast-cancer-information-and-positions/access-to-investigational.pdf. Updated July 2011. Accessed September 10, 2014.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Klopfenstein, M., Van Campen, L.E. & Garnett, T. Expanded Access Programs: Ethical and Practical Considerations for Biopharmaceutical Sponsors. Ther Innov Regul Sci 49, 352–358 (2015). https://doi.org/10.1177/2168479015578154
Published:
Issue Date:
DOI: https://doi.org/10.1177/2168479015578154